3C
SGMO

361 Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

361 Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-109,161
Closed -$695K – 378
2020
Q1 		$695K Buy
+109,161
New +$810K 0.32% 158
2018
Q2 		– Sell
-66,233
Closed -$1.26M – 386
2018
Q1 		$1.26M Buy
+66,233
New +$1.42M 0.31% 204

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

361 Capital's SGMO Position: Q2 2020 in Review

361 Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2020, closing a stake of 109,161 shares — an estimated $695K sold.

361 Capital first reported a position in SGMO in Q1 2018 and held it in 2 quarters. The position peaked at $1.26M in Q1 2018. 205 funds tracked by Wall St. Rank hold SGMO as of Q2 2020.

  • 361 Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2020 after selling out during the quarter.
  • 361 Capital sold 109,161 SANGAMO THERAPEUTICS INC shares in Q2 2020, an estimated $695K.
  • 361 Capital first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 2 quarters.
  • 361 Capital's SANGAMO THERAPEUTICS INC position peaked at $1.26M in Q1 2018.
  • 205 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.